Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients

被引:231
作者
Kramer, L
Bauer, E
Joukhadar, C
Strobl, W
Gendo, A
Madl, C
Gangl, A
机构
[1] Univ Vienna, Sch Med, Dept Med, A-1010 Vienna, Austria
[2] Univ Vienna, Sch Med, Dept Clin Pharmacol, A-1010 Vienna, Austria
[3] Christian Doppler Lab Specif Adsopt Technol, Krems, Austria
关键词
citrate; alkalosis; ionized calcium; cirrhosis; regional anticoagulation;
D O I
10.1097/01.CCM.0000084871.76568.E6
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives. To investigate pharmacokinetics and metabolism of sodium citrate in critically ill patients. To determine the risk of citrate accumulation in the setting of liver dysfunction (cirrhosis, hepatorenal syndrome). Design, Prospective cohort study. Setting. Intensive Care Unit, Department of Medicine IV, University Hospital Vienna. Patients. Consecutive critically ill cirrhotic (n = 16) and non-cirrhotic patients (n = 16). Interventions. Infusion of sodium citrate (0.5 mmol.kg(-1).hr(-1)) and calcium chloride (0.17 mmol.kg(-1).hr(-1)) for 2 hrs. Analysis of serial arterial blood samples. Measurements and Main Results: Total body clearance of citrate was normal in noncirrhotic critically ill patients but significantly reduced in cirrhotic patients (710 vs. 340 mL/min, p = .008). Citrate peak concentrations and concentration over time were increased by 65% and 114% in cirrhotic patients (p < .001), respectively; volumes of distribution were similar. Net metabolic changes were quantitatively similar, with pH and plasma bicarbonate concentrations increasing more slowly in cirrhotic patients. No citrate-related side effects were noted. Citrate clearance could not be predicted by standard liver function tests and was not appreciably influenced by renal function and Acute Physiology and Chronic Health Evaluation 11 scores. Conclusions: This first systematic study on citrate pharmacokinetics and metabolism in critically ill patients confirms a major role of hepatic citrate metabolism by demonstrating reduced citrate clearance in cirrhotic patients. Pharmacokinetic data could provide a basis for the clinical use of citrate anticoagulation in critically ill patients. Provided dose adaptation and monitoring of ionized calcium, citrate anticoagulation seems feasible even in patients with decompensated cirrhosis. Metabolic consequences of citrate infusion were not different between groups in this study but may be more pronounced in prolonged infusion.
引用
收藏
页码:2450 / 2455
页数:6
相关论文
共 26 条
[1]  
Apsner R, 1997, WIEN KLIN WOCHENSCHR, V109, P123
[2]   Dalteparin-induced alopecia in hemodialysis patients:: reversal by regional citrate anticoagulation [J].
Apsner, R ;
Hörl, WH ;
Sunder-Plassmann, G .
BLOOD, 2001, 97 (09) :2914-2915
[3]   Simplified citrate anticoagulation for high-flux hemodialysis [J].
Apsner, R ;
Buchmayer, H ;
Lang, T ;
Unver, B ;
Speiser, W ;
Sunder-Plassmann, G ;
Hörl, WH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) :979-987
[4]  
Apsner R, 1998, NEW ENGL J MED, V338, P131
[5]  
AUFEUVRE JP, 1992, PLASMAPHEREIS IMMUNO, P65
[6]  
Bohler J, 1996, J AM SOC NEPHROL, V7, P234
[7]   HEMODYNAMIC EFFECTS OF INTRAVENOUSLY ADMINISTERED SODIUM CITRATE [J].
BUNKER, JP ;
BENDIXEN, HH ;
MURPHY, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1962, 266 (08) :372-+
[8]   HYPOCALCEMIA DURING RAPID BLOOD-TRANSFUSION IN ANESTHETIZED MAN [J].
DENLINGER, JK ;
NAHRWOLD, ML ;
GIBBS, PS ;
LECKY, JH .
BRITISH JOURNAL OF ANAESTHESIA, 1976, 48 (10) :995-1000
[9]  
DIAZ J, 1994, TRANSPLANT P, V26, P3669
[10]   REDUCING THE HEMORRHAGIC COMPLICATIONS OF HEMODIALYSIS - A CONTROLLED COMPARISON OF LOW-DOSE HEPARIN AND CITRATE ANTICOAGULATION [J].
FLANIGAN, MJ ;
VONBRECHT, J ;
FREEMAN, RM ;
LIM, VS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1987, 9 (02) :147-153